Samuel Z Goldhaber, MD
Professor of Medicine
Harvard Medical School
Director, Venous Thromboembolism Research Group
Co-Director, Anticoagulation Management Service
Cardiovascular Division
Brigham and Women's Hospital
Boston, MA
Clotblog with Dr Samuel Goldhaber
View all posts »CURRENT OASIS-7: Doubling the clopidogrel dose in ACS patients undergoing PCI
Oct 22, 2009 09:30 EDT-
1Comments
-
Read later
The CURRENT OASIS-7 trial published during ESC showed a remarkable reduction in myocardial infarction and in-stent thrombosis for patients whose loading dose of clopidogrel was doubled. With a dataset of over 17,000 patients, the results are remarkable and uptake in cath labs has been rapid. With time, how will the OASIS-7 regimen compare with novel antiplatelet agents and approaches to antiplatelet testing?
CURRENT OASIS-7: Benefit to doubling clopidogrel dose in ACS patients undergoing PCI
Your comments
 |
 |
 |
||
 |
|
 |
||
 |
 |
 |
||
 |
|
|
 |
|
 |
 |
 |
||
 |
|
|
 |
|
|
|
|
||
|
||||
You must be a member (with full membership) to post a comment.
Already a member?
Enjoy all the benefits of theheart.org
With full membership, you can check out our educational and editorial content, search the site, receive our newsletters, join discussions, download slides and much more.
Membership is free!
